thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof.

In yet another aspect, there is provided a kit for identifying candidate agents capable of modulating the interaction between a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof, the kit comprising the first polypeptide, the second polypeptide and at least one candidate agent.

In one ~~aspect~~example, there is disclosed herein use of an agent, which decreases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof, in the manufacture of a medicament for treating, inhibiting or suppressing tumor growth

In another ~~aspect~~example, there is disclosed herein use of an agent which decreases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof in the manufacture of a medicament for inhibiting tumor metastasis.

In yet another ~~aspect~~example, there is disclosed herein use of an agent which increases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof in the manufacture of a medicament for enhancing wound healing.

In one example, there is provided a method of treating, inhibiting or suppressing tumor growth comprising: administering an agent which decreases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof.

In another example, there is provided a method of inhibiting tumor metastasis comprising: administering an agent which decreases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof.

In yet another example, there is provided a method of enhancing wound healing comprising: administering an agent which increases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the

15. A kit for identifying candidate agents capable of modulating the interaction between a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof, the kit comprising the first polypeptide, the second polypeptide and at least one candidate agent.

16. An isolated complex between ZO-2/TJP2 and a Snail zinc finger transcription factor family member.

17. The complex of claim 16, wherein the Snail zinc finger transcription factor family member is SNAI2 (Slug).

18. The complex of claim 17, wherein the binding portion of ZO-2/TJP2 and SNAI2 (Slug) is at the guanylate kinase (GUK) domain of ZO-2/TJP2.

19. The complex of claim 18, wherein the guanylate kinase (GUK) domain of ZO-2/TJP2 comprises SEQ ID NO: 26.

20. Use of the isolated complex of any one of claims 16-19 as a biomarker for detecting cancer.

21. An antibody directed against the binding portion of ZO-2/TJP2 and SNAI2 (Slug) at the guanylate kinase (GUK) domain of ZO-2/TJP2.

22. The antibody of claim 21, wherein the guanylate kinase (GUK) domain of ZO-2/TJP2 comprises SEQ ID NO: 26.

5

15. A kit for identifying candidate agents capable of modulating the interaction between a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof, the kit comprising the first polypeptide, the second polypeptide and at least one candidate agent.

16. Use of an agent, which decreases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof, in the manufacture of a medicament for treating, inhibiting or suppressing tumor growth .

17. Use of an agent which decreases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof in the manufacture of a medicament for inhibiting tumor metastasis.

18. Use of an agent which increases the binding of a first polypeptide and a second polypeptide, wherein the first polypeptide is ZO-2/TJP2 or a functional variant thereof and the second polypeptide is a Snail zinc finger transcription factor family member or a functional variant thereof in the manufacture of a medicament for enhancing wound healing

19. An isolated complex between ZO-2/TJP2 and a Snail zinc finger transcription factor family member.

20. The complex of claim 19, wherein the Snail zinc finger transcription factor family member is SNAI2 (Slug).

21. The complex of claim 20, wherein the binding portion of ZO-2/TJP2 and SNAI2 (Slug) is at the guanylate kinase (GUK) domain of ZO-2/TJP2.

22. The complex of claim 21, wherein the guanylate kinase (GUK) domain of ZO-2/TJP2 comprises SEQ ID NO: 26.

23. Use of the isolated complex of any one of claims 19-22 as a biomarker for detecting cancer.

24. An antibody directed against the binding portion of ZO-2/TJP2 and SNAI2 (Slug) at the guanylate kinase (GUK) domain of ZO-2/TJP2.

25. The antibody of claim 24, wherein the guanylate kinase (GUK) domain of ZO-2/TJP2 comprises SEQ ID NO: 26.